Skip to main content
Midas Edge

Neuphoria Therapeutics Inc.

For the period ended Mar 31, 2025. Filed May 20, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 20, 2025

NEUP$2.78+0.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statement of Changes in Shareholders' Equity

Condensed Consolidated State ment of Changes in Shareholders' Equity (Unaudited)

Stock · Additional · AccumulatedOther · Total
Common Shares · Subscription · Paid-In · Comprehensive · Accumulated · Shareholders'
Shares · Amount · Receivable · Capital · Loss · Deficit · Equity
Balance at June 30, 20241,103,954$11$-$198,481,027$(3,013,595)$(177,977,071)$17,490,372
Exercise of pre-funded ADS warrants339,4083-406--409
Share issue costs---(227,747)--(227,747)
Share-based compensation---26,736--26,736
Other comprehensive income----585,381-585,381
Net loss-----(804,787)(804,787)
Balance at September 30, 20241,443,362$14$-$198,280,422$(2,428,214)$(178,781,858)$17,070,364
Exercise of pre-funded ADS warrants185,2972-218--220
Share issue costs---(111,777)--(111,777)
Share-based compensation---20,970--20,970
Other comprehensive loss----(1,288,433)-(1,288,433)
Net loss-----(1,943,349)(1,943,349)
Balance at December 31, 20241,628,659$16$-$198,189,833$(3,716,647)$(180,725,207)$13,747,995
Issuance of common stock in connection with our ATM facility, net of offering costs of $0.1 million225,3073-1,162,501--1,162,504
Share-based compensation---20,466--20,466
Other comprehensive loss----(195,818)-(195,818)
Net income-----11,262,16111,262,161
Balance at March 31, 20251,853,966$19$-$199,372,800$(3,912,465)$(169,463,046)$25,997,308
Balance at June 30, 2023679,970$7$-$187,554,244$(3,058,783)$(162,484,905)$22,010,563
Issuance of ADS shares, net of issuance costs of $0.5 million175,0722(5,648,976)6,261,512--612,538
Share-based compensation---140,448--140,448
Other comprehensive loss----(63,469)-(63,469)
Net loss-----(5,472,568)(5,472,568)
Balance at September 30, 2023855,042$9$(5,648,976)$193,956,204$(3,122,252)$(167,957,473)$17,227,512
Issuance of ADS shares, net of issuance costs of $0.3 million and stock subscription receivable36,073-(311,426)288,784--(22,642)
Collection of subscription receivable--5,648,976---5,648,976
Share-based compensation---746,936--746,936
Other comprehensive income----451,085-451,085
Net loss-----(4,554,424)(4,554,424)
Balance at December 31, 2023891,115$9$(311,426)$194,991,924$(2,671,167)$(172,511,897)$19,497,443
Exercise of common stock options-------
Issuance of ADS shares, net of issuance costs of $0.1 million104,7981-1,436,932--1,436,933
Collection of subscription receivable--311,426---311,426
Share-based compensation---40,031--40,031
Other comprehensive loss----(561,948)-(561,948)
Net loss-----(2,778,148)(2,778,148)
Balance at March 31, 2024995,913$10$-$196,468,887$(3,233,115)$(175,290,045)$17,945,737
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.